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Background: Patients on warfarin with traumatic intracranial hemorrhage (ICH) 
often require pharmacological reversal of warfarin-induced coagulopathy. We 
compared outcomes among patients who received 4-factor prothrombin complex 
concentrate (PCC), fresh frozen plasma (FFP) or no reversal to assess the real-world 
impact of PCC on elderly patients with traumatic intracranial hemorrhage on 
warfarin. 
 
Study Design: This was a retrospective analysis of 150 patients on preinjury 
warfarin. Data was abstracted from the electronic medical record (EMR) of an 
academic level 1 trauma center for patients age 65 years and greater on warfarin 
therapy admitted with a traumatic ICH between January 2013 and December 2018. 
Primary outcomes were ICH progression on follow-up computed tomography (CT) 
scan, in-hospital mortality, need for surgical intervention. Trends in use over time 
and costs of the reversal agents were also analyzed. 
 
Results: Of 150 patients eligible for analysis, 41 received FFP, 60 received PCC, and 
49 were not reversed with either of those reversal agents. On multivariable analysis, 
patients who were not reversed [OR 0.25, 95% CI (0.31 – 0.85)] or were female [OR 
0.38, 95% CI (0.17 – 0.88)] were less likely to experience progression of their initial 
bleed on follow-up CT. SDH increased the risk of hemorrhagic progression [OR 
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3.69, 95% CI (1.27 – 10.73)]. There was no difference between groups with respect to 
in-hospital mortality or the need for neurosurgical intervention. Over time, the use 
of reversal with PCC increased, while use of FFP and not reversing declined (p 
<0.001). Regarding costs, PCC was significantly more expensive to administer per 
patient than FFP.  
 
Conclusion: In older patients with traumatic ICH on warfarin, use of a reversal 
agent was associated with progression of the ICH. The choice of reversal agent did 
not impact mortality or the need for surgery. Therefore, some ICH patients may not 
require warfarin reversal, and the apparent benefits to PCC use in retrospective 
studies may be related to the increased use of PCC in patients who would have not 














The Case for Anticoagulation Therapy 
 Hypercoagulable states are associated with many adverse outcomes, 
including disabling stroke and deadly pulmonary emboli (PE). Other common 
pathologies that predispose patients to poor outcomes related to blood clotting are 
atrial fibrillation (AF) and venous thromboembolism (VTE), the latter of which 
includes deep venous thrombosis (DVT) and PE. Due to the significant vascular 
risks, AF and VTE are significantly associated with increased morbidity and 
mortality. Therefore, medical management becomes crucial in controlling overall 
prognosis.  
 AF is caused by an underlying cardiac abnormality that leads to 
uncoordinated atrial arrhythmias and irregular ventricular responses. Inflammation 
and fibrosis within the cardiac tissues, valvular abnormalities, or even an ectopic 
signal arising within the pulmonary veins can all be underlying causes of this 
abnormal atrial rhythm. With the loss of coordinated atrial contractions comes a 
decrease in adequate ventricular filling and stroke volume. While some cases of AF 
are asymptomatic and therefore clinically silent, more severe manifestations can 
include dyspnea, palpitations, and pulmonary edema [1], as the heart becomes 
unable to propel blood systemically. Additionally, the loss of forward blood flow 
means more blood is static within the heart, which contributes to an increased risk 
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of intracardiac thrombus formation. Dislodgement of these thrombi can then lead to 
stroke [2]. 
 AF is the most common clinically significant cardiac arrhythmia in the 
world, with an estimated global burden of 33.5 million people [3]. In the United 
States alone, approximately 2.3 million people have a diagnosis of AF, with that 
number being projected to increase to 5.6 million by 2050 due primarily to a 
substantial increase in the elderly population, who develop AF in greater numbers 
than their younger counterparts. In the United States, AF is more often seen in 
elderly, Caucasian men, and can affect anywhere from 8 – 10% of people over 80 
years old [4]. In fact, the prevalence of AF doubles with each increasing decade of 
age [5]. AF incurs a four-to-fivefold increased risk of stroke, and has been estimated 
to be responsible for up to 15% of all strokes nationwide [6]. Due to both the high 
prevalence and significant stroke risk, AF is the most common dysrhythmia treated 
in medical practices, and is responsible for up to a third of hospital admissions 
associated with dysrhythmias [5], making it a significant clinical burden in the 
healthcare realm. 
 VTE is another significant condition caused by an underlying pathology in 
the coagulation cascade that leads to the inappropriate formation of clots within the 
vasculature. DVT refers to the formation of clots within the deep veins, most often 
those of the lower limbs and the pelvis. Also included under the category of VTE 
are PE, which are due to dislodged thrombi that travel within the venous system 
and become fixed in the pulmonary vasculature. DVT is a significant risk factor for 
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the development of PE: nearly half of all patients with untreated DVT can develop a 
PE in as little as 3 months [7]. Acquired risk factors that are known to contribute to 
an increased risk of VTE development include advanced age, immobility, recent 
surgery, obesity [8], hormone replacement therapy [9], and malignancy [10]. Genetic 
conditions, albeit rarer, are also important to consider as underlying causes of VTE 
development. These conditions are linked to either decreased levels of or 
inadequate responses to the body’s natural anticoagulants, and include Factor V 
Leiden, prothrombin G20210A, and inherited deficiencies in proteins C, S, and/or 
antithrombin [8].  
 VTE is the third most common acute cardiovascular disease after myocardial 
infarction (MI) and stroke. The condition affects a large portion of the U.S. 
population with an incidence rate ranging between 300,000 – 600,000 new cases per 
year. VTE also disproportionately affects the elderly, with nearly 60% of all cases 
occurring in patients over 70 years old [11]. The mortality rate is significant: up to 
30% of patients die within 30 days of diagnosis, and as high as 25% of PE cases 
alone present as sudden death. Even with appropriate medical management, nearly 
one third of all patients can experience a recurrence of VTE within 10 years, with a 
“definite” recurrence rate of 17.6% and a “probable” rate of 30.4% [12]. 
 With such significant morbidity and mortality associated with these disease 
states, pharmacological management becomes key in improving outcomes. 
Anticoagulation therapy has been a mainstay of the medical regimen for these 
conditions for decades. One important and popular therapy that has had significant 
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benefit in targeting the coagulative sequelae associated with AF and VTE is 
warfarin, an oral anticoagulant with a mechanism of action that works by 
preventing the activation of several coagulation factors necessary for clot formation. 
From its discovery in 1933 [13] to its approval for stroke prevention in AF patients by 
the Federal Drug Administration (FDA) in 1954 [14], warfarin use has exploded over 
time, with nearly 30 million prescriptions for the medication now written annually 
in the United States [15]. In the following section, we will begin to explore both the 
benefits as well as the adverse effects associated with warfarin use when managing 
these hypercoagulable conditions. 
 
Benefits and Dangers of Warfarin 
 Warfarin is in a class of medications known as the vitamin K antagonists 
(VKAs). VKAs work by inhibiting the enzyme vitamin-K epoxide reductase [16], 
which is responsible for the post-translational carboxylation of multiple factors 
necessary in the coagulation cascade. These include factors II, VII, IX, X, as well as 
proteins C and S [17]. Inhibition of this step results in the inactivation of these factors 
and creates an antithrombotic effect that counteracts the prothrombotic state seen in 
conditions like AF and VTE. 
 Multiple trials have proven the clinical benefit to warfarin use in stroke 
prevention for patients with nonvalvular AF. The 1990 study by the Boston Area 
Anticoagulation Trial for Atrial Fibrillation (BAATAF) investigators found an 86% 
reduction in stroke risk in patients receiving long-term, low-dose warfarin therapy 
 10 
compared to control patients who did not receive warfarin but who could choose to 
take aspirin [18]. In the 1991 Stroke Prevention in Atrial Fibrillation (SPAF) 
randomized trial, warfarin was found to significantly reduce the rate of ischemic 
stroke and systemic embolism when compared to placebo, with an overall 54% 
reduction in disabling ischemic stroke or vascular deaths in those patients who 
received the medication [19]. The 1992 Veterans Affairs Stroke Prevention in 
Nonvalvular Atrial Fibrillation (SPINAF) study was another randomized trial that 
found warfarin was associated with a 0.79 relative reduction in cerebral infarction 
risk compared to placebo [20].   
 Additional studies directly compared the benefits of warfarin to another 
popular antithrombotic medication, aspirin, which was considered to be the gold 
standard antiplatelet for the prevention of arterial thromboses [21]. These further 
studies also found significant benefits to warfarin over aspirin therapy in 
preventing stroke in AF patients, including the European Atrial Fibrillation Trial 
(EAFT) [22] and the SPAF II trial [23]. Given the ample evidence for warfarin’s clinical 
benefit in reducing thromboembolic risk in AF patients, it becomes clear why for 
years the American Heart Association, American College of Cardiology, and Heart 
Rhythm Society (AHA/ACC/HRS) guidelines consistently included warfarin as a 
class I recommended pharmacotherapy for antithrombotic AF management [24]. Of 
note, warfarin was eventually overtaken by the non-vitamin K anticoagulants 
(NOACs) in January 2019 as the preferred therapy for stroke prevention in AF 
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patients following the publication of several seminal randomized trials [25], yet this 
particular topic is beyond the scope of this paper.  
 Similarly, VKAs have long been a staple in the medical management of VTE. 
The earliest landmark randomized control trial in 1960 investigating the use of 
VKAs for treatment of PE found that patients who received heparin and the VKA 
coumarin-derivative nicoumalone (of note, warfarin is also a coumarin derivative) 
had a significant reduction in mortality attributed to PE compared to the untreated 
control group: 0% vs. 26% [26]. Today, VKAs, primarily warfarin, are recommended 
as long-term secondary prophylaxis following a VTE event following the initial 
regimen of IV thrombolytics and/or heparin [27].  
 There is strong evidence linking the use of VKAs to reduced VTE recurrence 
rates, a finding with great clinical significance given that 10-year VTE recurrence 
rates can reach levels as high as 30% [12]. In one trial, patients with acute DVT 
treated initially with intravenous (IV) heparin were randomized to receive either 
fixed, low-dose subcutaneous heparin or warfarin sodium as secondary 
prophylaxis. The total recurrence rate after 12 weeks of follow-up was 47% in the 
heparin group, as opposed to 0% in the warfarin group [28].  One trial went further, 
and followed 508 patients for an average of 4.3 years, all of whom had previously 
received 6.5 months of full-dose anticoagulation therapy for VTE. The patients were 
randomized to receive either long-term, low-intensity warfarin or placebo. The 
researchers found a significant risk reduction of 64% for recurrent VTE in the 
therapeutic group relative to the placebo group. Long-term warfarin use was also 
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found to be associated with a 48% reduction in the overall composite endpoint of 
recurrent VTE, major hemorrhage, or death [29]. 
 Warfarin has many potential clinical uses beyond AF and VTE. These 
include warfarin use for the primary prevention of ischemic coronary events as an 
adjunct to aspirin, as long-term treatment for patients with acute MI, as an 
antithrombotic in patients with prosthetic heart valves, and even for other less well-
supported indications, such as AF due to valvular (as opposed to nonvalvular) 
heart disease, mitral stenosis, dilated cardiomyopathy, and in patients with one or 
more episodes of systemic thromboembolism [30].  Altogether, warfarin has proven 
to be a highly effective anticoagulant for a variety of clinically relevant indications, 
which explains its vast use among medical practitioners for patients with 
thromboembolic conditions. However, finding the appropriate balance between 
antithrombotic activity and the innate risk of bleeding that comes with any 
anticoagulative medication, especially when considering long-term therapy, can be 
difficult to achieve. Excessive, systemic anticoagulation with VKAs can lead to 
bleeding so severe as to prompt rapid, pharmacological reversal in order to prevent 
catastrophic and fatal hemorrhage. Despite its benefits, warfarin use can be as 
dangerous as the thrombotic complications it works to prevent if its use is not 
carefully monitored by patients and care practitioners alike. 
 Bleeding associated with warfarin use is a serious medical complication, and 
there is a myriad of factors to be aware of that can increase this risk. These include 
increasing age, a history of uncontrolled hypertension (HTN), acute or chronic 
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alcohol use, liver disease, active or a recent history of bleeding lesions or bleeding 
disorders, and concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) 
and some antibiotics [31]. Of the non-modifiable factors, the general consensus is that 
increasing age is the major risk factor that increases bleeding risk [31].  
However, another significant risk factor for warfarin-associated bleeding that 
has been heavily reviewed in the literature is poor control of the International 
Normalized Ratio (INR), which is a quantitative measure of the time it takes for clot 
formation to occur in a measured sample of plasma. Since its introduction in the 
1980s [32], INR has become the test of choice to monitor patients on VKAs, and the 
VKA dose is considered adequate if the INR is within a “therapeutic” range. These 
exact recommended values vary depending on the underlying clinical pathology 
being treated with VKA therapy, but typically ranges between 2.0 – 3.5 [33]. An 
elevated INR outside of the therapeutic range might signify that the dose of 
anticoagulant is too high, which can translate to an increased risk of bleeding [34]. 
Several studies have shown that bleeding rates in patients taking warfarin increases 
with higher presenting INR values [35] [36]. INR can therefore be a reliable predictor 
for bleeding risk in warfarin patients. 
Up to 20% of patients on warfarin will experience a bleeding complication 
due to excessive anticoagulation per year, and the fatality rate from such bleeds can 
range between 1 – 3% [37]. In a study investigating rates of hemorrhage in AF 
patients specifically, bleeding risk was found to be the highest during the first 30 
days of warfarin therapy, while the cumulative incidence of associated hemorrhage 
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increased over time to a value of 8.7% at 5 years following initiation of therapy. 
Patients older than 75 years of age were at significantly higher risk, with a 4.6% risk 
per person-year compared to a 2.9% risk in those 75 or younger. 62.6% of those 
hemorrhages involved the gastrointestinal (GI) tract, and 18.1% of those admitted to 
the hospital for warfarin-related bleeds died within 7 days of discharge [38].  
Due to such high mortality rates related to warfarin-associated bleeding, 
they are a large topic of discussion in the literature. ICH, particularly when related 
to traumatic injury, is a feared complications of anticoagulation use and has been 
associated with significantly higher mortality rates. For example, in one 
retrospective analysis warfarin use was found to be associated with a 6-fold 
increased mortality risk for ICH after blunt traumatic brain injury (TBI) compared 
to patients with TBI who were not on preinjury anticoagulation [39]. Another study 
investigating elderly patients with head injuries found that preinjury warfarin use 
both increased the ICH risk by 40% and doubled the risk of 30-day mortality 
compared to those not on warfarin [40].  
 One possible reason that could explain the high mortality rates seen in 
warfarin-associated ICH that has been supported in the literature may relate to the 
increased risk of hemorrhagic expansion in anticoagulated patients compared to 
non-anticoagulated patients. In a 2001 French study, researchers compared 3 groups 
of patients for analysis: those admitted due to anticoagulant-related ICH, a 
randomly selected group of patients admitted with spontaneous ICH, and those 
without ICH but who were on anticoagulation therapy. It was found that ICH 
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volumes in anticoagulated patients were significantly higher than those seen in 
spontaneous ICH based on CT scan measurements [41]. Another study conducted by 
Flibotte and colleagues at the Massachusetts General Hospital saw no effect of 
warfarin on initial ICH volume at presentation, but warfarin was found to be the 
only predictor of in-hospital hemorrhagic expansion. ICH expansion was then 
found to trend towards increased mortality, with warfarin patients overall being at 
significant risk for death, even after controlling for the initial ICH volume [42].    
 ICH is a significant adverse effect of anticoagulation therapy with severe 
effects on morbidity and mortality. Warfarin plays a considerable role in these 
outcomes, and the risk factors associated with adverse bleeding can be difficult to 
control, given that the major contributing risk factor, age, is non-modifiable. In 
acute situations where bleeding must be promptly addressed, reversal of 
anticoagulation is warranted. There are multiple pharmacological reversal agents 
that can counteract the antithrombotic mechanisms of warfarin and help prevent 
the sequelae of major bleeding. Prompt correction of coagulopathy associated with 
over-anticoagulation is recommended by current guidelines [43], and the following 
section aims to give a comprehensive discussion of important reversal agents that 






Efficacy of Warfarin Reversal Agents 
 There are 3 pharmacological therapies available that can reverse the effects of 
warfarin: fresh frozen plasma (FFP), the prothrombin complex concentrates (PCCs), 
and phytonadione (vitamin K). Each agent has its own advantages and 
disadvantages, but the general consensus is that prompt reversal of warfarin in 
patients presenting with dangerous bleeds, such as an ICH, can contribute to 
decreased morbidity and mortality. Although a supratherapeutic INR is often 
implicated in increased bleeding risk, current guidelines suggest that for any 
patient presenting with a life-threatening bleed, prompt administration of reversal 
agents is warranted regardless of the presenting INR value [44]. In one study 
comparing times to reversal in anticoagulated traumatic ICH patients, patients in 
whom reversal therapy was initiated in under 2 hours as part of a rapid treatment 
protocol had both decreased rates of worsening ICH progression, as well as 
significantly lower mortality, than patients receiving reversal under an older 
protocol, in which it took more than 4 hours to initiate treatment [45]. Multiple 
guidelines, including those by the AHA/ASA [46] and the Neurocritical Care 
Society/Society of Critical Care Medicine [47], highly recommend immediate 
reversal in VKA patients presenting with ICH. The greatest source of debate within 
the literature in recent years, therefore, has not been whether reversal is warranted 
for warfarin-related hemorrhage, but instead involves the question of which of the 3 
available reversal agents are most effective at both quickly counteracting the effects 
of the medication and improving overall outcomes in bleeding patients.  
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 Full discussion of phytonadione will be limited in scope, primarily because it 
has little use as an agent for acute bleeding in emergency situations due to 
inappropriately long response times in reversing warfarin. In one randomized trial 
comparing omission of warfarin therapy to omission of warfarin therapy combined 
with oral phytonadione therapy, the mean time to achieve an INR £4 for over-
anticoagulated patients presenting with an initial INR of 6 – 9 was 1.4 days. 
Although significantly faster than omission of warfarin therapy alone (which took 
2.6 days in comparison) [48], this would be an inadequate treatment for a patient 
presenting with a more time-sensitive, warfarin-related coagulopathy, such as an 
ICH. Another disadvantage to vitamin K, especially if given at high doses, is that it 
can make patients refractory to future warfarin therapy when anticoagulation is 
eventually restarted [49]. Use of low doses of oral phytonadione as a monotherapy is 
therefore currently limited to patients who do not require urgent warfarin reversal 
[50].  
 Historically, FFP in combination with vitamin K had long been the standard 
of care in reversing the effects of over-anticoagulation [51] [52]. FFP can be prepared 
from either whole blood or plasma, and contains all of the clotting factors inhibited 
by warfarin and more, including fibrinogen, antithrombin and tissue factor 
pathway inhibitor. With appropriate dosing, FFP administration can increase the 
levels of deficient clotting factors by up to 30% [53], making it an effective therapy 
for warfarin reversal. In the United States, FFP is the most widely used coagulation 
factor replacement therapy [54], and this use has only been increasing over time. In 
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2008, 4.5 million units of FFP were transfused in the United States, compared to 3.9 
million units in 2001 [55], for an average of now nearly 12,000 units used daily 
nationwide. One of the most common indications for FFP use is for warfarin 
reversal, as has been consistently cited in analyses conducted within both the 
United States [56] and abroad [57].   
 Despite its widespread use, administration of FFP is limited by several 
factors. Significant effort is required in preparing the infusions, FFP has a relatively 
slower therapeutic onset compared to other reversal alternatives (i.e. PCC), and 
there are many clinical adverse side effects associated its use. To adequately 
prepare a unit of FFP, the sample first undergoes type-specific matching, thawing, 
and delivery from the blood bank [54]. The thawing step can take anywhere from 30 
– 60 minutes alone [58]. These steps can delay initiation of treatment, which is 
significant especially in time-sensitive situations. Even if prepared promptly, FFP 
has a rather slow therapeutic effect and can take 7 – 32 hours to achieve effective 
INR reversal in warfarin patients presenting with major hemorrhage [54], which is 
not ideal for life-threatening bleeding in which prompt reversal is required.  
 After transfusion, there are several serious adverse effects associated with 
FFP to be aware of. Of all blood products, FFP is the major cause of the life-
threatening condition known as transfusion-related acute lung injury (TRALI). The 
underlying pathophysiology of TRALI is speculated to be related to an 
inappropriate immune response involving either donor antibodies, human 
leukocyte antigen (HLA) responses, and/or active recipient lung leukocytes that are 
 19 
reacting to certain biological components of the donor’s blood products. The 
endpoint of these aberrant immune responses is significant pulmonary endothelial 
damage [59]. Symptoms and clinical findings of TRALI include acute respiratory 
distress, non-cardiac pulmonary edema, bilateral infiltrates on chest x-ray, 
tachycardia, and hypoxemia within 6 hours of the transfusion. The absence of 
concomitant risk factors for the development of lung injury, such as sepsis, 
pneumonia, and shock, increase the clinical suspicion for TRALI in a recently 
transfused patient [60]. Statistically, transfusion of every 1 in 2,000 units of a plasma-
containing blood component leads to an episode of TRALI, and fatality rates after 
diagnosis can range between 5 – 25% [61]. In one 5-year retrospective review study, 
FFP was associated with 50% of fatal TRALI cases, with red blood cells (RBCs), 
platelet products, and cryoprecipitate-reduced plasma responsible for the rest [59]. 
TRALI is overall the highest leading cause of transfusion-related morbidity and 
mortality in the United States [62], making it a serious clinical consequence of FFP 
use. 
Another significant risk to FFP use is volume overload, otherwise known as 
transfusion-associated circulatory overload (TACO). FFP in particular is a major 
risk factor for developing TACO due to the high volumes of plasma required to 
achieve adequate therapeutic effects. The number of FFP units transfused has also 
been shown to strongly correlate with the subsequent development of fluid 
overload [62]. After TRALI, TACO is the second-leading cause of transfusion-related 
mortality in the United States. Rates of TACO following FFP administration varies, 
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with studies reporting values between 1.5 – 6%. Patients with TACO were found to 
have increased rates of in-hospital mortality, and both significantly longer hospital 
and intensive care unit (ICU) stays [63] [64].  
FFP use is associated with other unique side effects. Since FFP is derived 
from donated human blood products, its administration can increase the risk of 
infectious disease transmission and immune reactions. These include viral, 
bacterial, parasitic, and prion diseases, febrile and allergic reactions, and ABO 
blood group incompatibility [65]. In a 2008 study, FFP transfusion in critically ill 
patients in an inpatient surgical ICU (SICU) was found to be significantly associated 
with higher rates of subsequent ventilator-associated pneumonias, bloodstream 
infections, and septic shock. The researchers attributed these increased risks to a 
transfusion-related phenomenon known as immunomodulation, which involves 
alterations in the systemic immune response due to transfusion of 
immunosuppressive proteins and/or disrupted white blood cell (WBC) products 
within the plasma [66]. These reactions, taken together with previously mentioned 
complications such as TRALI and TACO, are serious adverse effects that should be 
weighed with the benefits to FFP use prior to administration. 
An alternative to FFP as a VKA-reversal therapy are the PCCs. PCC is a 
plasma-derived factor concentrate that was originally developed for the treatment 
of hemophilia B as a source of factor IX [67]. PCC contains variable amounts of the 
vitamin K-dependent coagulation factors II, VII, IX, and X, and can be further 
classified based on the quantity of factor VII present in the concentrate: 3-factor 
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PCC contains negligible amounts, while 4-factor PCC contains therapeutically 
restorative levels (for the remainder of this paper, any mentions of PCC will refer 
solely to the 4-factor preparation, unless otherwise specified).  
The first successful documentation of PCC as an anticoagulation reversal 
therapy was in a 1976 randomized trial comparing 3-factor PCC to intravenous 
vitamin K therapy. The researchers found that PCC was associated with more 
rapid, albeit less sustained, reversal of both the prothrombin and partial 
thromboplastin times compared to vitamin K alone [68]. A 2007 comprehensive 30-
year review of all prospective trials comparing PCC to other reversal agents, 
conducted prior to PCC’s official approval as a reversal therapy by the FDA, found 
that PCC was associated with multiple clinical benefits, including more rapid INR 
correction, effective factor replacement, and decreased risks of thrombotic adverse 
events [52]. In 2013, PCC was officially approved by the FDA for the reversal of 
coagulopathy in over-anticoagulated patients [69], which is now the primary 
indication for its use. It is now rarely indicated as replacement therapy in patients 
with congenital factor deficiencies [70] – the original reason for its development – 
and has largely been replaced either by concentrates of individual clotting factors or 
recombinant factor products, especially following the introduction of these 
products in the 1990s [67] [71].  
First, preparing PCC units for infusion is a significantly less intensive process 
relative to FFP. PCC does not require cross-matching, is stored at room temperature 
(and therefore does not require thawing), undergoes viral inactivation to reduce the 
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risk of infectious transmission, and can be completely infused in 15 – 30 minutes [72] 
[50]. These benefits are especially ideal for acute situations in which preparation time 
should be minimized. Additionally, TRALI, a feared complication of FFP use, is 
unlikely with PCC because the concentrates do not contain leukocytes that could 
trigger aberrant immune responses in donors [73]. PCC is also very unlikely to cause 
TACO because the units are freeze-dried to remove all water particles (e.g. 
lypophilized), and PCC can therefore be administered in smaller volumes [74]. For 
comparison, FFP is typically administered at a dose of 15 mL/kg, while an 
equivalent PCC dose can be given at a volume of 1-2 mL/kg [74]. In one randomized 
control trial comparing the two reversal modalities for patients presenting with 
VKA-associated coagulopathy, the median infusion volumes needed to achieve 
therapeutic effect for PCC and FFP were 99.4 and 813.5 mL, respectively [75].  
 However, PCC is not without its own set of adverse side effects. As with any 
transfusion of blood products, anaphylactic reactions have been associated with 
PCC administration, and since most PCC preparations contain heparin, heparin-
induced thrombocytopenia (HIT) has been documented as well. Although PCC is 
pretreated to inactivate most viral pathogens, contamination of the products with 
non-enveloped viruses has occurred. Thrombogenic complications including stroke, 
MI, disseminated intravascular coagulation (DIC), and DVT have also all been 
attributed to PCC use [70] [74], albeit that composite risk remains low at 1.4%, 
according to a recent literature review [52]. Since most of these adverse effects are 
quite rare, PCC is overall a safe and effective therapy for warfarin reversal. 
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Armed now with a better understanding of the primary agents available for 
VKA reversal, the next important question to consider is whether there is a superior 
reversal therapy that is associated with the best clinical outcomes in situations 
requiring reversal of anticoagulation in patients presenting with severe bleeding, 
especially ICH. In the upcoming section, we conduct a brief literature review of the 
clinical studies that directly compare PCC to FFP for urgent reversal, with a 
primary focus on life-threatening ICH associated with anticoagulation therapy. 
 
PCC vs. FFP: A Superior Agent? 
 Current guidelines have now shifted their recommendations to PCC for the 
urgent reversal of VKAs in life-threatening warfarin-related bleeds [76], given that 
PCC has been shown repeatedly in numerous clinical trials and reviews to have 
many advantages over FFP. One of the earliest such reports that aimed to directly 
compare the 2 reversal therapies for this purpose was a 1997 prospective 
investigation by Makris and colleagues conducted in the United Kingdom, in which 
patients requiring urgent reversal of their oral anticoagulation therapy received 
either FFP or PCC. PCC use was associated with complete INR correction in all 
patients and greater restoration of hemostatically effective levels of clotting factors 
(especially factor IX), whereas in contrast, the INR failed to correct adequately in all 
patients receiving FFP. Nearly 2 decades before the FDA would officially approve 
PCC as a reversal agent for severe, anticoagulation-associated bleeding, the authors 
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of this study strongly concluded that PCC is the only effective option for correcting 
coagulopathies in patients with life-threatening hemorrhage [77].  
Several systematic analyses of studies comparing reversal agents in patients 
requiring urgent warfarin reversal also have found benefits to PCC use. One meta-
analysis of 13 relevant studies found that PCC use was associated with a lower risk 
of all-cause mortality, higher proportion of hemostasis, greater and more rapid INR 
normalization, and lower risk of post-transfusion volume overload compared to 
FFP [78]. Another 2017 analysis by Harrison et al. found that PCC was associated 
with a 3.65% risk reduction in 30-day mortality relative to FFP [79].  
 Benefits to PCC were also seen in the results of several randomized 
controlled trials, some of which were included for review in the meta-analyses 
discussed above. In one prospective trial conducted across numerous sites in both 
the United States and Europe, VKA patients presenting with both acute major 
bleeding and elevated INR ³2.0 were randomized to receive either FFP or PCC for 
urgent reversal. PCC use was found to be associated with more rapid INR 
reduction (defined as an INR £1.3 half an hour after infusion) and higher levels of 
plasma coagulation factors relative to FFP [75]. In a similar randomized trial by 
Goldstein et al., patients received vitamin K with either concomitant PCC or FFP 
therapy for rapid VKA reversal. PCC was found to be superior to FFP in achieving 
both effective hemostasis and rapid INR reduction [80]. In both of these trials, rates 
of adverse events such as thromboembolism, fluid overload, late bleeding, and 
death, were similar between treatment groups.  
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Those results were later confirmed in a more recent 2016 randomized trial 
conducted in Germany. This study was unique in that it was the first randomized 
trial to compare reversal therapies in patients specifically presenting with VKA-
related ICH, especially since the previous 2 randomized trials comparing PCC to 
FFP had few patients with this specific bleeding complication in the study cohorts 
(for example, only 2 of the 181 bleeding patients in the Goldstein study required a 
neurosurgical procedure). In the German study, only 9% of FFP patients achieved 
the primary endpoint of an INR £1.2 within 3 hours of treatment initiation, as 
opposed to 67% of PCC patients. All deaths associated with hematoma expansion 
were in the FFP group, again suggesting inadequate hemostasis in patients 
receiving FFP as opposed to PCC [81].  
While the German study is the only randomized trial to compare reversal for 
warfarin-related ICH, the researchers excluded trauma-related ICH. However, 
evidence for PCC’s benefits in clinical scenarios specifically involving traumatic 
ICH has also been seen in other observational and retrospective studies. In a 2013 
study of patients presenting with an ICH requiring urgent reversal, PCC achieved 
significantly faster INR reversal than FFP [82]. A similar 2014 observational study 
likewise found that PCC was associated with a faster time to INR reversal, as well 
as a significantly shorter delay in the time to neurosurgical intervention [83]. Use of 
PCC also has been shown to decrease the incidence of ICH progression in patients 
presenting with traumatic, warfarin-related bleeds [84]. 
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The literature clearly supports the use of PCC for urgent reversal in life-
threatening bleeds. However, one area that has received relatively less attention is 
the comparison of reversal agents for ICH specifically in patients of advanced age. 
This is a particularly important population to consider given that patients over 65 
years of age are more likely to be on an anticoagulative medication such as 
warfarin, advanced age is one of the strongest independent risk factors for 
anticoagulative-related bleeding, and the second leading cause of injury after motor 
vehicle crashes in this population are falls, which can further increase the risk of 
bleeding. Trauma-related ICH in an elderly patient on anticoagulation is a 
substantial risk that can have devastating consequences. In fact, preinjury warfarin 
use in elderly brain injured patients has been associated with far worse outcomes 
relative to those seen in their younger counterparts.  
In one retrospective analysis of elderly TBI patients, oral anticoagulation 
with warfarin was significantly associated with increased mortality, need for 
neurosurgical intervention, and risk of in-hospital death. These risks were not 
associated with the use of preinjury antiplatelet medications, such as aspirin or 
clopidogrel [85]. In older patients, an INR as low as 2 has been associated with 
increased severity of TBIs, overall mortality, risks of ICH, and risks of subsequent 
ICH-associated mortality (in contrast, recall that the therapeutic INR range for 
warfarin patients ranges between 2.0 – 3.5) [86]. In one retrospective analysis of 
patients 55 years or older presenting with TBI, use of oral anticoagulation and 
antiplatelets was related to more in-hospital mortality, progression of the bleed, 
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development of new hemorrhagic foci, and discharge to a care facility compared to 
patients not taking those preinjury medications [87]. 
With the projected elderly population age 65 years and older expected to 
reach 52 million by the year 2020 [88], understanding the indications, benefits, risks, 
and the most effective methods for warfarin reversal are crucial to ensure the best 


















Statement of Purpose 
This retrospective study aims to identify differences in clinical outcomes, costs, and 
trends associated with the use of FFP, PCC, or no reversal agent in patients 65 years 
old and older with a traumatic ICH on preinjury warfarin presenting to our 
academic level 1 trauma center. Our study is unique from prior studies in that we 
also consider in our comparison the absence of the use of a reversal agent. We 
hypothesize that the use of PCC will result in improved clinical outcomes 


















Data & Study Sample 
After obtaining approval from the Yale Human Investigations Committee, 
we retrospectively reviewed all patients 65 years of age or older on preinjury 
warfarin diagnosed with traumatic ICH admitted to Yale New Haven Hospital, an 
academic Level 1 trauma center from January 2013 through December 2018 (n=190) 
via the internal electronic medical record (EMR) system. The ICH types included 
were: subarachnoid hemorrhage (SAH), subdural hemorrhage (SDH), epidural 
hemorrhage (EPH), and/or intraparenchymal hemorrhage (IPH) identified through 
the trauma registry. Patients who were admitted for comfort measures only (n=18), 
were deemed to have a non-survivable injury (n=3), had no follow-up head CT scan 
(n=12), or received both FFP and PCC as part of their treatment (n=8) were 
excluded from analysis. This yielded a final sample of 150 patients.  
Follow-up CT scans were obtained at 6 hours after the initial CT scan. The 
study sample was then stratified based on the type of reversal agent used: PCC, 
FFP, or no reversal agent. Data on baseline demographics (sex, race), mechanism of 
injury, admission INR, Injury Severity Score (ISS), head Abbreviated Injury Score 
(AIS), Glasgow Coma Scale (GCS) score, whether the patient was transferred from 
an outside hospital (OSH), comorbidities (hypertension (HTN), diabetes mellitus 
(DM), coronary artery disease (CAD)), use of vitamin K therapy and preinjury use 




The 3 primary outcomes were ICH progression on follow-up CT scan, need 
for craniotomy, and in-hospital mortality. We chose to include ICH progression as 
one of our primary outcomes because we believe it to be a more sensitive indicator 
of the efficacy of reversal agent. ICH progression was defined as a radiology report 
that indicated increasing size and/or expansion of a head bleed on follow-up CT 
scan relative to the initial CT scan obtained on admission. Secondary outcomes 
included hospital length of stay (LOS), admission to the intensive care unit (ICU), 
ICU LOS, need for mechanical ventilation, total days spent on mechanical 
ventilation, change in neurologic exam, and number of hours until the INR 
decreased to a value of <1.2. The costs associated with the use of reversal agent per 
patient were calculated by averaging the number of units of either FFP or PCC 
given, and using available institutional labor cost data, cost per unit of FFP and the 
average wholesale price (AWP) of PCC, respectively, to determine the expenses. 
 
Statistical Analysis 
All statistical analysis was performed using SAS version 9.4 (Carry, NC). The 
Chi-square test was used to compare categorical variables, and the independent t-
test was used to compare normally distributed variables. Variables with non-
normal distributions were compared using the Kruskal-Wallis test. Bonferroni 
corrections were used to adjust for multiple comparisons. Logistic regression was 
 31 
used to assess for differences in outcomes with models adjusted for demographics, 
admission INR, use of vitamin K, concomitant antiplatelet therapy, head AIS score, 
and GCS score. Use of any antiplatelet medications were grouped together into one 
variable given the few patients on medications other than aspirin. Lastly, the 
Cochran-Armitage test was used to assess for trends in the use of the various agents 
over time. All statistical analysis was performed by Dr. Kevin Schuster, Associate 
Professor of Surgery (Trauma) in the Yale Medicine section of General Surgery, 

















Of 150 eligible patients with complete data, 41 patients received FFP (27.3%), 
60 received PCC (40%), and 49 (32.7%) were not reversed. There were no significant 
differences between groups with regards to age, sex, race, mechanism of injury, 
type of ICH, ISS, AIS, GCS, and concomitant use of antiplatelet therapy (Table 1). 
Among all three groups, admission INR was highest in the group that received FFP 
(2.94) and lowest in the group not reversed (2.02, p = 0.006), but was not statistically 
significant when comparing INR values for PCC and FFP groups (p = 0.592). There 
was no difference between groups for the comorbidities diabetes (DM) (p = 0.983) 
or coronary artery disease (CAD) (p = 0.094), but patients who received PCC were 
more likely to have hypertension (88%) (p = 0.021) compared to those who received 
FFP (71%) or no agents (67%). Finally, patients who received PCC were more likely 
to have received vitamin K (90%) than any other patient group (p < 0.001).  
  
  PCC (n=60) FFP (n=41) 
No Reversal 
(n=49) p-value 
Age (mean, SD)  81.9 (8.1) 81.2 (9.7) 81.3 (7.3) 0.889 
Male (n, %)  35 (58.3) 18 (43.9) 24 (49) 0.334 
Race (n, %)     0.951 
 White 50 (83) 34 (83) 44 (90)  
 Black 4 (7) 3 (7) 3 (6)  
 Other 6 (10) 4 (10) 2 (4)  
Mechanism of injury (n, %)     0.248 
 Fall 59 (98) 38 (93) 48 (98)  
 Other 1 (2) 3 (7) 1 (2)  
ICH Type (n, %)     0.566 
 SAH 29 (48.3) 23 (56.1) 32 (65.3) 0.207 
 SDH 38 (63.3) 28 (68.3) 25 (51) 0.868 
 EPH 2 (0.033) 1 (0.024) 0 (0) 0.453 
 IPH 5 (0.083) 2 (0.049) 5 (10.2) 0.646 
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Admission INR (mean, SD)  2.77 (1.3) 2.94 (1.9) 2.02 (1.4) 0.006 
ISS (mean, SD)  15.8 (8.5) 15.2 (8.0) 13.6 (7.4) 0.341 
AIS head (median, IQR)  2 (1, 3) 1 (1, 2) 2 (1, 3) 0.864 
GCS (mean, SD)  14.4 (1.7) 14.05 (2.4) 13.96 (2.6) 0.441 
Transfer from OSH (n, %)  14 (23.3) 14 (34.1) 11 (22.4) 0.376 
Comorbidities (n, %)     0.767 
 HTN 53 (88) 29 (71) 33 (67) 0.021* 
 DM 17 (28) 11 (27) 14 (29) 0.983 
 CAD 22 (37) 11 (27) 24 (49) 0.094 
Concomitant antiplatelet 
therapy (n, %)  16 (26.7) 12 (29.3) 21 (42.9) 0.173 
Administered Vitamin K (n, 
%)  54 (90) 33 (80.4) 16 (32.7) <0.001* 
Table 1: Demographic information of patients who received PCC, FFP, and no reversal 
agent. 4-factor prothrombin concentrate (PCC), fresh frozen plasma (FFP), subarachnoid 
hemorrhage (SAH), subdural hemorrhage (SDH), epidural hemorrhage (EPH), 
intraparenchymal hemorrhage (IPH), International Normalized Ratio (INR), Injury 
Severity Score (ISS), Abbreviated Injury Score (AIS), outside hospital (OSH), 
hypertension (HTN), diabetes mellitus (DM), coronary artery disease (CAD), standard 
deviation (SD), interquartile range (IQR). 
 
Of all patients, 38% (n=57) experienced progression of their bleed according 
to follow-up CT scans. On bivariate analysis, patients who received FFP were more 
likely to have had ICH progression (51.2%) compared to those who received PCC 
(43.3%) or no reversal agent (20.4%) (p = 0.006). There was no difference in the rates 
of mortality or the need for surgical intervention between the three groups (Table 
2).  
For secondary outcomes, FFP patients had longer hospital LOS, spent more 
time in the ICU of those admitted to the ICU, and more often required mechanical 
ventilation. Time to reversal was most rapid in the PCC group (median 10.5 hours, 
IQR 6-17.5 vs. 21 hours, IQR 15-36 in FFP group, p = 0.002). There was no significant 
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difference between groups in ICU admissions, total number of days spent on 
mechanical ventilation, or worsening mental status (Table 2). 
 





ICH Progression (n, %) 26 (43.3) 21 (51.2) 10 (20.4) 0.006* 
Need for craniotomy (n %) 9 (15) 8 (19.5) 3 (6.1) 0.157 
Mortality (n, %) 2 (3.3) 0 (0) 2 (4.1) 0.448 
LOS (days, median, IQR) 4 (3-7) 6 (3-13) 4 (2-5) 0.024* 
ICU Admit (n, %) 34 (56.7) 23 (56.1) 19 (38.8) 0.128 
ICU LOS (median, IQR) 7 (3, 18) 7 (4, 13) 4 (2, 15) 0.422 
Mechanical ventilation (n, %) 4 (6.7) 9 (22) 4 (8.2) 0.041* 
Vent Days (median, IQR) 0 (0, 0) 1 (0, 4) 0 (0, 0) <0.001* 
Worsening mental status (n, %) 18 (30) 13 (31.7) 11 (22.4) 0.563 
Time to INR <1.2 (hours, median, 
IQR) 10.5 (6, 17.5) 21 (15, 36) N/A 0.002* 
Table 2: Primary and secondary outcomes of patients who received PCC, FFP, and no 
reversal agent. Length of stay (LOS), intensive care unit (ICU).  
 
On multivariable analysis, no reversal and female gender were associated 
with a decreased likelihood of ICH progression on follow-up CT scan, while the 
presence of SDH was associated with progression of the bleed (Table 3). Admission 
INR, co-administration of vitamin K, and use of concomitant antiplatelet therapy 
were not associated with ICH progression. Multivariable analysis of mortality 
demonstrated only higher presenting GCS (OR 0.75, 95% CI [0.60 – 0.95]) as 
protective. The absence of reversal (OR 0.78, 95% CI [0.07 – 8.96]) and use of FFP 
(OR 0.42, 95% CI [0.04 – 4.44]) compared to PCC did not impact mortality. 
Multivariable analysis of the need for craniotomy demonstrated no effect for not 





(OR) 95% CI P Value 
IPH 1.35 0.31 – 5.98 0.689 
SAH 2.06 0.74 – 5.74 0.165 
SDH 3.69 1.27 – 10.73 0.017* 
EDH 0.57 0.01 – 38.98 0.794 
PCC Reference   
No Reversal Agent Used 0.25 0.31 – 0.85 0.010* 
FFP 1.13 0.44 – 2.90 0.070 
Female 0.38 0.17 – 0.88 0.023* 
Admission INR 1.01 0.79 – 1.30 0.923 
Administered Vitamin K 2.13 0.73 – 6.24 0.168 
Concomitant Antiplatelet 
Therapy 1.56 0.63 – 3.86 0.331 
Head AIS - 1 1.25 0.34 – 4.64 0.031* 
Head AIS – 2 0.54 0.13 – 3.11 0.870 
Head AIS – 3 0.57 0.02 – 1.39 0.970 
Head AIS – 4 0.17 0.02 – 1.39 0.100 
Head AIS - 5 Reference   
GCS 0.84 0.70 – 1.00 0.050 
Table 3: Multivariable analysis of predictors of ICH progression on follow-up CT scan. 
 
Throughout the study period, the usage of reversal agent by year also 
significantly shifted (Table 4, Figure 1). Use of FFP decreased from 68% in 2013 to 
3% in 2018, and use of PCC increased from 0% in 2013 to 76% by 2018 (p <0.001). 
The proportion of patients receiving no reversal also decreased from approximately 
30% to a low of 21% in 2018 (p <0.001).  
Cost calculations were based on 41 patients who received FFP at an average 
of 3.54 units per person. FFP costs at our institution are 35 USD per unit, with an 
additional 16.25 USD cost associated for lab labor, bringing the total cost per unit of 
FFP to 51.25 USD. Therefore, the average cost per patient to administer FFP was 
approximately 181 USD. Sixty patients received PCC at an average of 1,725 units 
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per person. At an AWP of 2.90 USD per unit, the average cost to administer PCC 
per patient was 5,003 USD.   
 
Reversal Agent 2013 2014 2015 2016 2017 2018 
No Reversal Agent 32 38 30 52 29 21 
FFP 68 29 35 19 13 3 
PCC 0 33 35 29 58 76 
Table 4: Therapy used (no reversal agent, FFP, or PCC) in % over time. 
 
































While there are many studies that have compared outcomes between the use 
of PCC versus FFP for warfarin reversal in head trauma patients, they have not 
included patients observed without reversal. This study is significant in that it 
demonstrates an association between lower rates of hemorrhagic progression in 
older patients who are not reversed, in contrast to our original proposed 
hypothesis. Equivalently, patients who did receive reversal agents were 
paradoxically more likely to experience bleed progression, especially in the subset 
of patients receiving FFP. This was similarly observed in the prospective, 
observational Frontera et al. study, which compared outcomes in patients 
presenting with warfarin-related ICH who received either PCC, FFP, or PCC and 
FFP. The authors found that using FFP alone for warfarin reversal was significantly 
associated with greater rates of major hemorrhage, defined as new or worsening 
ICH, anemia requiring transfusion, or GI bleed, after administration than with PCC 
[89]. However, our study was different in that we examined a third group of ICH 
patients that underwent no warfarin reversal.  
This finding is important because we concomitantly observed that the 
proportion of patients receiving no reversal in our institution overall decreased 
since the introduction of PCC. We speculate that this is indicative of a lower clinical 
threshold for clinicians to provide warfarin reversal when a drug, i.e. PCC, with 
presumed fewer side effects than the prior standard of care is readily available. 
Therefore, improvements in patient outcomes when retrospectively comparing PCC 
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to FFP, as was seen in a large proportion of the prior literature, are likely partially 
artifact in both our study and in others that only compared those two treatment 
groups, and did not consider this third group of patients who received no reversal 
agent. Patients once deemed to be at low risk for bleed progression are now likely 
being included in higher numbers in the PCC treatment groups, even though these 
patients would likely not have been reversed at all prior to the FDA approval of 
PCC. Because the group with no reversal also had comparatively better outcomes, 
without differences in baseline GCS, head AIS, or other clinical variables likely 
associated with the decision to reverse, we believe clinicians use other subjective 
parameters to effectively identify patients who are likely to do well without 
pharmacological reversal. Also implied in these findings is the likelihood that many 
patients who were reversed, especially with FFP, ultimately did not benefit from 
reversal. Although the risk is likely low, these patients could have experienced the 
potential for harm due to thromboembolic events or other medication side effects 
and there was increased cost. 
Similar to prior studies, PCC therapy was associated with more rapid 
correction of the INR relative to FFP. It also correlated to shorter hospital stays and 
fewer requirements for mechanical ventilation. This is despite the fact that in this 
study population, there were no differences in severity of the initial injury. The 
improvements in outcome measures between the two treatments may therefore be 
related to the smaller fluid loads associated with PCC administration relative to that 
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of FFP, an advantage to PCC use that we explored in-depth in the introduction 
section.  
Additionally, although initial INR values were statistically similar when 
comparing the PCC and FFP patients and were highest in reversed patients, INR 
was ultimately not found to be associated with an increased likelihood of bleed 
progression on multivariable analysis. This further strengthens the inference that 
reversal based solely on presenting INR may ultimately not be beneficial to a 
substantial number of patients presenting with traumatic ICH. This lack of 
association between INR and severity of bleeding has likewise been seen in prior 
studies. In a 2005 study investigating rapid warfarin reversal in patients presenting 
with ICH, it was found that neither the initial GCS nor INR value in these patients 
were able to reliably identify patients with an ICH. Patients presenting with an ICH 
had a median INR of 2.7, compared to 2.5 in patients without an ICH, a difference 
that was statistically insignificant [45]. Although all patients in our study population 
presented with an ICH and we specifically were comparing rates of hemorrhagic 
expansion, we likewise found that there was no significant difference in the 
presenting INR value in patients requiring reversal, yet did see subsequently 
significant differences in bleed progression. 
Unlike many of the outcomes seen in prior studies, we found no significant 
difference in mortality between patients who received either of the two reversal 
agents or no reversal. Use of a reversal agent also had no relationship with the need 
for surgical intervention. In a study similar to ours, Zubkov and colleagues 
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demonstrated that INR at presentation was not associated with adverse outcomes, 
while other clinical findings, including presenting level of consciousness and initial 
ICH volume, were significant predictors of worse prognosis in patients presenting 
with an ICH on preinjury warfarin [90]. Going forward, it will therefore be important 
to understand the clinical rationale behind choosing to reverse an anticoagulated 
patient presenting with a traumatic ICH. Because injury severity was essentially 
similar between our treatment groups, there may have been unknown subjective 
factors that could better explain why physicians chose to initiate reversal, ones that 
perhaps had no influence on either mortality or the need for surgical treatment. 
These factors may have played a role in the decision to reverse, as well as the 
subsequent outcomes, in complex ways not identifiable in a retrospective study.  
Another unique aspect of our study is that we compared trends in the use of 
reversal agents over time. Throughout our study period, use of the reversal agent 
PCC increased significantly from 0% in 2013, which was prior to availability at our 
institution, to 78% in 2018. This increase in use was then associated with a 27-fold 
increase in costs to reverse a patient requiring treatment. PCC’s perceived 
advantages and improved availability relative to FFP likely prompted this change 
in practice. However, this cost is likely offset to some degree by the costs of the 
increased mechanical ventilation requirements and longer hospital stays 
experienced by the FFP group. To date, our study is the first in its kind to 
additionally compare these aspects of care, and follow-up investigations could 
expand this data on a national scale. 
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There are several limitations to our study. The most important aspect is its 
retrospective nature, which introduces potential selection bias. We are unable to 
discern whether a patient was reversed specifically to address either the presenting 
INR, radiological findings on CT scan, physical examination findings, 
symptomatology, or a combination of all of these. Physicians may have also chosen 
treatment based on unmeasured patient characteristics for which we cannot fully 
control and that may therefore not have been accurately reflected or recorded in the 
EMR, making data collection of these characteristics difficult. We did mitigate 
against this by controlling for all of the factors that were measurable and might 
impact a clinician’s decision to choose one method of reversal or no reversal. We 
were also limited by our choice of outcome. Though clinical deterioration, need for 
surgery and mortality are all impactful outcomes, our limited number of patients 
and therefore, our limited statistical power, may have prevented us from 
demonstrating outcome differences based on these measures. We do believe, 
however, that bleed progression is a likely surrogate for these more important 
outcomes if the study population is sufficiently large.  
Additionally, although the time to repeat CT scan is standardized at our 
institution, there was some variation in the timing that was beyond our control, and 
a few patients could not be included in our study because no repeat CT scan 
performed in a timely fashion. Although the use of follow-up CT scans is 
controversial, they may demonstrate outcome differences that would otherwise 
become evident if larger numbers of patients were studied. We chose this outcome, 
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therefore, as an intermediate marker. Similarly, the timing of repeat coagulation 
testing was not standardized at our institution, though prior studies have 
demonstrated similar decreased times to normalization of the pharmacologic 
coagulopathy. We were also limited in assessing overall charges based on 
institutional policy, and can only provide cost data for the reversal agents 
themselves. Lastly, all data analyzed were taken from one single academic 
institution, and cannot necessarily be extrapolated to other centers. This limitation 
will hopefully be addressed in a multi-institutional study to measure the impact of 
FFP, PCC or no reversal in a larger series. 
In conclusion, we have demonstrated that reversal of warfarin may not be 
beneficial in select patients. Although PCC provides for relatively effective and 
rapid reduction in INR, as was seen both in our study and in prior literature, the 
choice to reverse the coagulopathy ultimately did not affect mortality or the need 
for neurosurgical intervention. Over time, the use of the readily available PCC, with 
its improved side effect profile over FFP, was rapidly adopted, and likely led to the 
increased treatment of patients with PCC that would have been equally served with 
no treatment. This has significant effects on costs of therapy, as PCC was found in 
our institution to be significantly higher than those associated with FFP use. 
Moving forward, we should continue to further define those populations that may 
not benefit from, and might even be potentially harmed, by warfarin reversal in 
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